Assembly Biosciences Inc (NASDAQ:ASMB) – Stock analysts at William Blair issued their Q1 2019 earnings estimates for shares of Assembly Biosciences in a report issued on Friday. William Blair analyst Y. Xu anticipates that the biopharmaceutical company will post earnings per share of ($0.82) for the quarter. William Blair also issued estimates for Assembly Biosciences’ Q2 2019 earnings at ($0.84) EPS, Q3 2019 earnings at ($0.85) EPS and Q4 2019 earnings at ($0.87) EPS.
A number of other equities research analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a report on Wednesday, November 15th. BidaskClub lowered shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. ValuEngine lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. B. Riley assumed coverage on shares of Assembly Biosciences in a research note on Friday, January 5th. They issued a “neutral” rating and a $35.00 price objective on the stock. Finally, Jefferies Group upped their price objective on shares of Assembly Biosciences to $75.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $54.25.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $46.86, for a total value of $46,860.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders sold 3,000 shares of company stock worth $148,270. Company insiders own 19.60% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new position in Assembly Biosciences in the 4th quarter valued at approximately $326,000. Endurant Capital Management LP acquired a new position in Assembly Biosciences in the 4th quarter valued at approximately $430,000. Millennium Management LLC increased its stake in Assembly Biosciences by 30.4% in the 4th quarter. Millennium Management LLC now owns 133,666 shares of the biopharmaceutical company’s stock valued at $6,048,000 after buying an additional 31,195 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Assembly Biosciences by 46.8% during the 4th quarter. TIAA CREF Investment Management LLC now owns 72,331 shares of the biopharmaceutical company’s stock worth $3,273,000 after purchasing an additional 23,064 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of Assembly Biosciences by 16.1% during the 4th quarter. Teachers Advisors LLC now owns 28,964 shares of the biopharmaceutical company’s stock worth $1,311,000 after purchasing an additional 4,025 shares during the last quarter. Hedge funds and other institutional investors own 77.26% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Q1 2019 Earnings Estimate for Assembly Biosciences Inc (ASMB) Issued By William Blair” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://sportsperspectives.com/2018/03/14/q1-2019-earnings-estimate-for-assembly-biosciences-inc-asmb-issued-by-william-blair.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.